Palisade BIO
PALI on Nasdaq. Palisade BIO develops oral drugs for people with inflammatory bowel disease. Market value $254m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$1.49 a share, 13% above its 1-year low
Over the past year the price has ranged from $1.32 to $2.86.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | $0 | $250,000 | $0 | $0 |
| Operating margin | |||||
| Operating margin | n/a | n/a | -5228.0% | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | 0.01 | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.08bn | 0.01bn | 0.00bn | 0.15bn | 0.17bn |
Health checks
- Free cash flow positive0 of 4 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)2 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 126% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $11 million, compared with a loss of $3 million a year ago.
- 4306% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 1 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $0 |
| December 2024 | $0 |
| March 2025 | $0 |
| June 2025 | $0 |
| September 2025 | $0 |
| December 2025 | $0 |
| March 2026 | $0 |
| June 2026 | $500,000 |
| Quarter to | Amount |
|---|---|
| September 2024 | -$3m |
| December 2024 | -$3m |
| March 2025 | -$2m |
| June 2025 | -$3m |
| September 2025 | -$3m |
| December 2025 | -$9m |
| March 2026 | -$10m |
| June 2026 | -$11m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 20 March 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 124 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Platinum Investment ManagementPlatinum team | $4m | 0.9% | Added |
Largest holders overall
- Soleus Capital Management, L.P.$27mNew
- B Group$24m
- Ameriprise Financial$23mCut
- Jupiter Topco$22m
- BlackRock$22mAdded
- Octagon Capital Advisors LP$21m
- Perceptive Advisors$18mCut
- RA Capital Management, L.P.$15m
- Franklin Resources$12m
- Point72 Asset Management, L.P.$11mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
10 investors own more than 5%.
- JANUS HENDERSON GROUP PLCPassive investorat least 10.0%(filed with 1 related holder)Since 28 November 2025
- RA Capital Management, L.P.Passive investorat least 9.9%0.0 pts(filed with 3 related holders)Since 31 March 2026
- Perceptive Advisors LLCPassive investorat least 7.9%−2.1 pts(filed with 2 related holders)Since 31 March 2026
- Soleus Capital Master Fund, L.P.Passive investorat least 7.5%+2.1 pts(filed with 5 related holders)Since 30 June 2026
- Octagon Capital Advisors LPPassive investorat least 6.4%(filed with 2 related holders)Since 31 December 2025
- BlackRock, Inc.Passive investor6.0%Since 30 June 2026
- Franklin Resources, Inc.Passive investorat least 6.0%(filed with 3 related holders)Since 31 December 2025
- Ameriprise Financial, Inc.Passive investorat least 5.3%(filed with 1 related holder)Since 31 March 2026
- Armistice Capital, LLCPassive investorat least 5.0%−5.0 pts(filed with 1 related holder)Since 30 June 2025
- Squadron Capital Management LLCPassive investorat least 3.0%−5.5 pts(filed with 3 related holders)Since 31 December 2025
- Point72 Asset Management, L.P.Passive investorSold down below 5%Since 31 March 2026
- Commodore Capital LPPassive investorSold down below 5%Since 30 June 2026
- Deep Track Capital, LPPassive investorSold down below 5%Since 31 December 2025
| Holder | Stake | Since | |
|---|---|---|---|
JANUS HENDERSON GROUP PLC Passive investor | at least 10.0% (filed with 1 related holder) | 28 November 2025 | |
RA Capital Management, L.P. Passive investor | at least 9.9%0.0 pts (filed with 3 related holders) | 31 March 2026 | |
Perceptive Advisors LLC Passive investor | at least 7.9%−2.1 pts (filed with 2 related holders) | 31 March 2026 | |
Soleus Capital Master Fund, L.P. Passive investor | at least 7.5%+2.1 pts (filed with 5 related holders) | 30 June 2026 | |
Octagon Capital Advisors LP Passive investor | at least 6.4% (filed with 2 related holders) | 31 December 2025 | |
BlackRock, Inc. Passive investor | 6.0% | 30 June 2026 | |
Franklin Resources, Inc. Passive investor | at least 6.0% (filed with 3 related holders) | 31 December 2025 | |
Ameriprise Financial, Inc. Passive investor | at least 5.3% (filed with 1 related holder) | 31 March 2026 | |
Armistice Capital, LLC Passive investor | at least 5.0%−5.0 pts (filed with 1 related holder) | 30 June 2025 | |
Squadron Capital Management LLC Passive investor | at least 3.0%−5.5 pts (filed with 3 related holders) | 31 December 2025 | |
Point72 Asset Management, L.P. Passive investor | Sold down below 5% | 31 March 2026 | |
Commodore Capital LP Passive investor | Sold down below 5% | 30 June 2026 | |
Deep Track Capital, LP Passive investor | Sold down below 5% | 31 December 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $296,732 of shares on the open market. 2 sold $420,178.
- Williams Donald AllenDirectorBought
- Date
- 2 October 2026
- Shares
- 10,000
- Price
- $1.46
- Value
- $14,600
- Williams Donald AllenDirectorBought
- Date
- 1 October 2026
- Shares
- 10,000
- Price
- $1.42
- Value
- $14,200
- Baltera Robert Jr.DirectorBought
- Date
- 9 July 2026
- Shares
- 25,000
- Price
- $1.96
- Value
- $48,900
- Baltera Robert Jr.DirectorBought
- Date
- 8 July 2026
- Shares
- 20,000
- Price
- $1.99
- Value
- $39,798
- Baltera Robert Jr.DirectorBought
- Date
- 7 July 2026
- Shares
- 30,000
- Price
- $2.03
- Value
- $61,044
- Jones Mitchell LawrenceChief Medical OfficerSold
- Date
- 7 July 2026
- Shares
- 51,880
- Price
- $2.05
- Value
- $106,536
- Finley John DavidCEO, CFO, DirectorSold
- Date
- 7 July 2026
- Shares
- 146,798
- Price
- $2.07
- Value
- $303,343
- Baltera Robert Jr.DirectorBought
- Date
- 6 July 2026
- Shares
- 20,000
- Price
- $2.05
- Value
- $41,040
- Baltera Robert Jr.DirectorBought
- Date
- 2 July 2026
- Shares
- 10,000
- Price
- $1.98
- Value
- $19,800
- Baltera Robert Jr.DirectorBought
- Date
- 1 July 2026
- Shares
- 20,000
- Price
- $1.98
- Value
- $39,600
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 2 October 2026 | Williams Donald Allen Director | Bought | 10,000 | $1.46 | $14,600 |
| 1 October 2026 | Williams Donald Allen Director | Bought | 10,000 | $1.42 | $14,200 |
| 9 July 2026 | Baltera Robert Jr. Director | Bought | 25,000 | $1.96 | $48,900 |
| 8 July 2026 | Baltera Robert Jr. Director | Bought | 20,000 | $1.99 | $39,798 |
| 7 July 2026 | Baltera Robert Jr. Director | Bought | 30,000 | $2.03 | $61,044 |
| 7 July 2026 | Jones Mitchell Lawrence Chief Medical Officer | Sold | 51,880 | $2.05 | $106,536 |
| 7 July 2026 | Finley John David CEO, CFO, Director | Sold | 146,798 | $2.07 | $303,343 |
| 6 July 2026 | Baltera Robert Jr. Director | Bought | 20,000 | $2.05 | $41,040 |
| 2 July 2026 | Baltera Robert Jr. Director | Bought | 10,000 | $1.98 | $19,800 |
| 1 July 2026 | Baltera Robert Jr. Director | Bought | 20,000 | $1.98 | $39,600 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Palisade BIO’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 20 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 4 later 8-Ks.
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based upon the evaluation, our Chief Executive Officer concluded that, as of June 30, 2026, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting, as described below.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer, who is also our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026. Based upon the evaluation, our Chief Executive Officer concluded that, as of June 30, 2026, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting, as described below.
From the 10-Q filed 10 August 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.